Bigger And Smaller? Pfizer Pursues AstraZeneca But Hasn’t Given Up On A Split
Executive Summary
A Pfizer break up is still an option even if the company completes a mega-merger with AstraZeneca, CEO Ian Read said May 5. The company’s first quarter sales and earnings results highlighted how important completing a transaction could be for the company, with sales down 9% and earnings down 15%.